Novavax (NASDAQ: NVAX) reported Q3 EPS of ($2.15), $3.78 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $735 million versus the consensus estimate of $623.9 million.

GUIDANCE:

Novavax sees FY2022 revenue of $2 billion, versus the consensus of $2.04 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.